zepbound

New research reveals genes influence weight loss and nausea from Ozempic and Mounjaro. A study of nearly 28,000 people found specific genetic variants predict drug effectiveness and side effects. This breakthrough could lead to personalized prescriptions, helping doctors tailor treatments for millions. Doctors may soon use genetic tests to set realistic expectations and choose the best drug for each patient.

The FDA has approved zepbound (tirzepatide) for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity. The drug, coupled with a calorie-deficit diet and increased physical activity, significantly reduces apnea events and body weight. Side effects include nausea, diarrhea, and potential thyroid tumors. Contraindications include personal or family history of certain cancers and severe allergic reactions.

The introduction of new weight-loss drugs known as GLP-1s is transforming the U.S. healthcare landscape. These drugs, such as Eli Lilly's zepbound and Novo Nordisk's Wegovy, have shown significant weight loss results and potential beyond weight loss, including addressing addictive conditions. However, concerns about side effects and affordability arise, as these drugs come with high price tag. Despite challenges, pharmaceutical industry expects the GLP-1 drug market to reach $140 billion by 2032

The US FDA has approved the anti-diabetic drug zepbound (Tirzepatide) for managing obstructive sleep apnea (OSA) in obese adults. Eli Lilly plans to launch the drug in India by 2025, pending approvals. The treatment is expected to be a breakthrough by aiding weight reduction, which in turn improves breathing during sleep.

The US Food and Drug Administration (FDA) has approved Eli Lilly's weight loss drug, tirzepatide, under the brand name zepbound. The drug, previously available as Mounjaro for type 2 diabetes, will now be used for weight loss. zepbound will be available in the US by the end of the year at a list price of $1,059.87. Eli Lilly is launching a savings card program to reduce the cost of zepbound for patients. The approval was based on a trial of adults with obesity and weight-related medical problems.

Eli Lilly is cutting introductory zepbound prices again, with the lowest dose now $299 monthly for cash-pay customers, a $50 reduction. This move intensifies the price war with Novo Nordisk in the booming obesity drug market. Lilly's discounts, available via LillyDirect, aim to expand access to its weight-loss medications.

Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in those with diabetes after a year in a phase 2 trial. Despite higher discontinuation rates compared to other drugs, MariTide's monthly dosing could offer an advantage over weekly injections. Investors were slightly disappointed with the results.

MBX Biosciences has successfully raised $163.2 million in its U.S. IPO by pricing shares at $16 each, giving the company a valuation of $482.5 million. The biotechnology firm is working on treatments for chronic hypoparathyroidism and obesity, with its lead experimental candidate aimed at addressing low parathyroid hormone levels and another therapy in preclinical development for weight loss.

Novo Nordisk's CEO, Lars Fruergaard Jorgensen, will step down amidst market challenges and a significant stock price drop, exceeding 50% since June 2024. Increased competition from compounded versions of Ozempic and Wegovy, along with Eli Lilly's zepbound gaining market share, contributed to the decision.

Serena Williams shared new Instagram photos showing her slimmer figure in a pink silk dress while enjoying life after tennis. The 23-time Grand Slam champion previously revealed she used the GLP-1 medication zepbound for health reasons. At the same time, Novak Djokovic’s comments and Serena Williams’ presence in the ITIA testing pool have fueled fresh speculation about a possible tennis comeback.

GLP-1 drugs, synthetic versions of a natural hormone, are revolutionizing weight loss and type 2 diabetes treatment. By mimicking the body's satiety signals and slowing digestion, these medications help individuals eat less and lose significant weight. While generally safe with manageable side effects, their effectiveness is maximized when paired with lifestyle changes and medical guidance. Read below to know more!

America’s adult obesity rate has finally begun to dip after years of stagnation — down to 37% in 2025 from nearly 40% in 2022. The drop coincides with a surge in the use of anti-obesity drugs, now taken by roughly one in eight adults.

A casual chat about weight loss between a US envoy and Belarus's leader, Alexander Lukashenko, unexpectedly paved the way for releasing over 120 political prisoners. The personal exchange, involving a prescription drug, helped break the ice for crucial negotiations on sanctions relief and prisoner swaps, ultimately reuniting families and easing US restrictions on key Belarusian exports.

Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an average 12% body weight loss in a Phase 3 trial. The study, involving overweight or obese adults, revealed significant weight reduction and improved cardiovascular markers.

Originally developed for diabetes, GLP-1 drugs like Ozempic are showing remarkable potential in combating addiction. Emerging research suggests these medications can dampen cravings for alcohol and drugs by influencing the brain's reward system. While still in early stages, clinical trials and early patient experiences indicate a significant new therapeutic avenue for addiction treatment, offering hope for a complex societal crisis.

New research reveals a strategy that leads to five times more weight loss than through popular drugs like Ozempic over two years. This strategy offers a more enduring solution for weight management. While medications show effectiveness, this strategy provides a greater and longer-lasting reduction, highlighting the importance of long-term outcomes in obesity treatment. Comprehensive, personalised care remains key.

The FDA has approved a daily pill version of Novo Nordisk's Wegovy, offering an oral alternative to injectable weight-loss drugs. Containing semaglutide, the pill demonstrated similar weight loss and side-effect profiles to its injectable counterpart in clinical trials. This new option aims to expand access for patients who prefer not to use injections.

A study on Tirzepatide by Eli Lilly revealed it significantly lowered type 2 diabetes risk in overweight pre-diabetic adults after three years of weekly injections. The drug, approved in November 2023, also prompted a 22.9% average body weight reduction. However, weight gain and diabetes progression resumed when treatment stopped. Detailed results are forthcoming.

Pfizer is significantly expanding its presence in the obesity treatment market by acquiring Metsera for $4.9 billion, offering a substantial premium per share. Metsera, while lacking marketed products, boasts several promising clinical programs. This strategic move reflects the surging demand for obesity treatments, currently dominated by Eli Lilly and Novo Nordisk.